Company news

Jazz Pharmaceuticals plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

August 19, 2025

Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider

August 13, 2025

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

August 4, 2025

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

August 4, 2025

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

July 21, 2025

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

July 9, 2025

Nuevocor Strengthens Board with Appointment of Thierry Abribat

July 7, 2025

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

June 30, 2025

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

June 9, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

June 8, 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

June 1, 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

June 1, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 28, 2025

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 20, 2025

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

May 5, 2025

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

April 29, 2025

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

April 24, 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

April 22, 2025

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

April 21, 2025

Jazz Pharmaceuticals Completes Acquisition of Chimerix

April 20, 2025

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 25, 2025

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

March 18, 2025

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

March 4, 2025

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

February 24, 2025

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

February 19, 2025

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

February 10, 2025

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

Jazz Pharmaceuticals Announces CEO Succession Plan

December 15, 2024

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

December 5, 2024

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

December 4, 2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

December 3, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

December 2, 2024

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 19, 2024

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

November 18, 2024

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

November 5, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

October 30, 2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

October 22, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 14, 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

September 15, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

September 8, 2024

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

September 4, 2024

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

September 3, 2024

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

September 2, 2024

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

August 21, 2024

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 20, 2024

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

July 30, 2024

Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

July 24, 2024

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

July 21, 2024

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

July 16, 2024

Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

July 8, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.